Rajkotupdates.news : zydus needle free corona vaccine zycov d

ZyCoV-D is a needle-free plasmid DNA vaccine developed by Zydus Cadila. It has received regulatory approval for emergency use in India for adolescents and adults aged 12 and above. The vaccine is administered using a needle-free applicator, resulting in painless delivery and reduced side effects [3]. In a study, researchers evaluated the efficacy of a needle-free injection system (NFIS) for delivering a COVID-19 DNA vaccine in rhesus macaques. Results showed that the 2 mg dose delivered by NFIS elicited significant IgG and neutralizing antibody titers, enhanced their titers post-virus challenge, induced lymphocyte proliferation and cytokine response, and minimized viral load post-infection. The vaccine is a three-dose vaccine administered at an interval of 0-28-56 days, with each dose administered at two different sites. It is expected to be available from December and will be supplied to the government at a cost of ₹358 per dose, excluding GST.

What is Zydus ?

Zydus Cadila is an Indian pharmaceutical company that was founded in 1952 by Ramanbhai Patel in Ahmedabad, Gujarat. The company is now one of the leading pharmaceutical companies in India and has a presence in over 50 countries worldwide. Zydus Cadila is committed to developing innovative and affordable healthcare solutions for people around the world.

The company has a diverse portfolio of products that includes branded formulations, generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and vaccines. Zydus Cadila has a strong focus on research and development and has invested heavily in this area over the years. The company has research centers in India, the US, and Europe, and has a team of over 1,200 scientists working on developing new drugs and therapies.

Zydus Cadila's research efforts have led to the development of several innovative drugs over the years. The company's drug NCE-1, for example, was the first-ever new chemical entity (NCE) developed by an Indian company to receive regulatory approval in the US. The drug is used to treat diabetes and has been a commercial success for the company.

In addition to developing new drugs, Zydus Cadila has also been at the forefront of developing vaccines. The company's vaccine portfolio includes vaccines for diseases such as hepatitis B, measles, mumps, rubella, and typhoid. The company has also developed India's first indigenously developed vaccine for swine flu.

Zydus Cadila's most recent vaccine development is the ZyCoV-D vaccine for COVID-19. The vaccine is a needle-free plasmid DNA vaccine that has been approved for emergency use in India. The vaccine has shown promising results in clinical trials, with studies showing that it elicits significant antibody titers, induces lymphocyte proliferation and cytokine response, and minimizes viral load post-infection.

The ZyCoV-D vaccine is administered in three doses at an interval of 0-28-56 days, with each dose administered at two different sites. The vaccine is expected to be available from December and will be supplied to the Indian government at a cost of ₹358 per dose, excluding GST.

Apart from vaccines and drugs, Zydus Cadila also has a strong presence in the consumer healthcare space. The company's consumer healthcare portfolio includes products such as skin creams, cough syrups, and pain relief balms. The company has also recently entered the nutraceuticals market with the launch of a range of products under the brand name 'Naturell'.

Zydus Cadila's commitment to innovation and affordable healthcare has earned the company several accolades over the years. In 2020, the company was ranked as the 4th most valuable pharmaceutical brand in India by Brand Finance. The company was also recognized as the 'Best Pharma Company of the Year' at the Indian Pharma Awards in 2019.

In conclusion, Zydus Cadila is a leading Indian pharmaceutical company that has made significant contributions to the healthcare industry over the years. The company's focus on research and development has led to the development of several innovative drugs and vaccines, including the ZyCoV-D vaccine for COVID-19. Zydus Cadila's commitment to affordable healthcare has also made it a trusted brand among consumers in India and around the world.

What is Zycov-d ?

ZyCoV-D is a needle-free plasmid DNA vaccine developed by Zydus Cadila. It has received regulatory approval for emergency use in India for adolescents and adults aged 12 and above. The vaccine is administered using a needle-free applicator, resulting in painless delivery and reduced side effects. In a study, researchers evaluated the efficacy of a needle-free injection system (NFIS) for delivering a COVID-19 DNA vaccine in rhesus macaques. Results showed that the 2 mg dose delivered by NFIS elicited significant IgG and neutralizing antibody titers, enhanced their titers post-virus challenge, induced lymphocyte proliferation and cytokine response, and minimized viral load post-infection. The vaccine is a three-dose vaccine administered at an interval of 0-28-56 days, with each dose administered at two different sites. It is expected to be available from December and will be supplied to the government at a cost of ₹358 per dose, excluding GST.